Why the study?
Does a Thoratec Biventricular Assist Device provide a successful bridge to recovery in a patient with severe, refractory postpartum cardiomyopathy?
Does a Thoratec Biventricular Assist Device provide a successful bridge to recovery in a patient with severe, refractory postpartum cardiomyopathy?
Biventricular assist devices can serve as a successful bridge to recovery in patients with severe, refractory postpartum cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Case report of BiVAD bridge-to-recovery in postpartum cardiomyopathy; hypothesis-generating and should not yet change practice.
A 25-year-old African-American woman developed shortness of breath 7 days after a spontaneous vaginal delivery. She was found by echocardiogram to have a left ventricular ejection fraction of 10% and was diagnosed with postpartum cardiomyopathy. Despite medical therapy including diuretics, an ace inhibitor, and a beta blocker, over the next 5 months, the patient had more than 12 hospital admissions for congestive heart failure. After accepting her in transfer, we placed her on multiple IV inotropes and observed no improvement. We then implanted a Thoratec Biventricular Assist Device. During 26 days of support, we conducted two weaning trials that documented return of cardiac function. We then pretreated her for 48 hours before device explantation. She was weaned off inotropic therapy over 2 weeks and discharged to home with normal cardiac function. Two years after explantation of the device, she has a left ventricular ejection fraction of 40% and is New York Heart Association functional class 1.
No takes yet. Share an insight, caveat, or question.
Zimmerman et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: